Brain metastases in non-small cell lung cancer: Prevalence, high-risk factors, and overall survival prognosis

1] Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L, et al. Non-small cell lung cancer with brain metastasis at presentation. Clin Lung Cancer. 2018 Jul;19(4):e373–9. WaqarSN SamsonPP RobinsonCG BradleyJ DevarakondaS DuL Non-small cell lung cancer with brain metastasis at presentation Clin Lung Cancer 2018 Jul 19 4 e373 9 Search in Google Scholar

[2] Naresh G, Malik PS, Khurana S, Pushpam D, Sharma V, Yadav M, et al. Assessment of Brain Metastasis at Diagnosis in Non-Small-Cell Lung Cancer: A Prospective Observational Study From North India. JCO Glob Oncol. 2021 Apr;7:593–601. NareshG MalikPS KhuranaS PushpamD SharmaV YadavM Assessment of Brain Metastasis at Diagnosis in Non-Small-Cell Lung Cancer: A Prospective Observational Study From North India JCO Glob Oncol 2021 Apr 7 593 601 Search in Google Scholar

[3] An N, Jing W, Wang H, Li J, Liu Y, Yu J, et al. Risk factors for brain metastases in patients with non–small-cell lung cancer. Cancer Med. 2018 Nov 8;7(12):6357–64. AnN JingW WangH LiJ LiuY YuJ Risk factors for brain metastases in patients with non–small-cell lung cancer Cancer Med 2018 Nov 8 7 12 6357 64 Search in Google Scholar

[4] He J, Wang X, Xiao R, Zuo W, Zhang W, Yao H. Risk factors for brain metastases from non-small-cell lung cancer. Medicine (Baltimore). 2021 Mar 5;100(9):e24724. HeJ WangX XiaoR ZuoW ZhangW YaoH Risk factors for brain metastases from non-small-cell lung cancer Medicine (Baltimore) 2021 Mar 5 100 9 e24724 Search in Google Scholar

[5] Rice SR, Molitoris JK, Vyfhuis MAL, Edelman MJ, Burrows WM, Feliciano J, et al. Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis. Clin Lung Cancer. 2019 Jan;20(1):e107–14. RiceSR MolitorisJK VyfhuisMAL EdelmanMJ BurrowsWM FelicianoJ Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis Clin Lung Cancer 2019 Jan 20 1 e107 14 Search in Google Scholar

[6] Ernani V, Stinchcombe TE. Management of Brain Metastases in Non–Small-Cell Lung Cancer. J Oncol Pract. 2019 Nov;15(11):563–70. ErnaniV StinchcombeTE Management of Brain Metastases in Non–Small-Cell Lung Cancer J Oncol Pract 2019 Nov 15 11 563 70 Search in Google Scholar

[7] Descourt R, Greillier L, Perol M, Ricordel C, Auliac JB, Falchero L, et al. First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer Immunol Immunother CII. 2023 Jan;72(1):91–9. DescourtR GreillierL PerolM RicordelC AuliacJB FalcheroL First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study) Cancer Immunol Immunother CII 2023 Jan 72 1 91 9 Search in Google Scholar

[8] Wakuda K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, et al. Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression. Lung Cancer Amst Neth. 2021 Jan;151:60–8. WakudaK YabeM KodamaH NishiokaN MiyawakiT MiyawakiE Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression Lung Cancer Amst Neth 2021 Jan 151 60 8 Search in Google Scholar

[9] Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017 Jun 1;3(6):827–31. SperdutoPW YangTJ BealK PanH BrownPD BangdiwalaA Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) JAMA Oncol 2017 Jun 1 3 6 827 31 Search in Google Scholar

[10] Yoshida H, Kim YH, Iwatsubo S, Sakaguchi C, Sakamori Y, Nagai H, et al. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan. Oncology. 2020;98(7):460–7. YoshidaH KimYH IwatsuboS SakaguchiC SakamoriY NagaiH Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan Oncology 2020 98 7 460 7 Search in Google Scholar

[11] Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015 Sep;10(9):1240–2. TravisWD BrambillaE BurkeAP MarxA NicholsonAG Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2015 Sep 10 9 1240 2 Search in Google Scholar

[12] Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016 Jan;11(1):39–51. GoldstrawP ChanskyK CrowleyJ Rami-PortaR AsamuraH EberhardtWEE The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2016 Jan 11 1 39 51 Search in Google Scholar

[13] Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649. OkenMM CreechRH TormeyDC HortonJ DavisTE McFaddenET Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 1982 Dec 5 6 649 Search in Google Scholar

[14] Lwanga SK, Lemeshow S, Organization WH. Sample size determination in health studies : a practical manual [Internet]. World Health Organization; 1991 [cited 2023 Jul 9]. Available from: https://apps.who.int/iris/handle/10665/40062 LwangaSK LemeshowS Organization WH Sample size determination in health studies : a practical manual [Internet] World Health Organization 1991 [cited 2023 Jul 9]. Available from: https://apps.who.int/iris/handle/10665/40062 Search in Google Scholar

[15] Zhu H, Zhou L, Guo Y, Yang G, Dong Q, Zhang Z, et al. Factors for incidence risk and prognosis in non-small-cell lung cancer patients with synchronous brain metastasis: a population-based study. Future Oncol Lond Engl. 2021 Jul;17(19):2461–73. ZhuH ZhouL GuoY YangG DongQ ZhangZ Factors for incidence risk and prognosis in non-small-cell lung cancer patients with synchronous brain metastasis: a population-based study Future Oncol Lond Engl 2021 Jul 17 19 2461 73 Search in Google Scholar

[16] Hao Y, Li G. Risk and prognostic factors of brain metastasis in lung cancer patients: a Surveillance, Epidemiology, and End Results population-based cohort study. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2023 Sep 1;32(5):498–511. HaoY LiG Risk and prognostic factors of brain metastasis in lung cancer patients: a Surveillance, Epidemiology, and End Results population-based cohort study Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP 2023 Sep 1 32 5 498 511 Search in Google Scholar

[17] Cacho-Díaz B, Cuapaténcatl LD, Rodríguez JA, Garcilazo-Reyes YJ, Reynoso-Noverón N, Arrieta O. Identification of a high-risk group for brain metastases in non-small cell lung cancer patients. J Neurooncol. 2021 Oct;155(1):101–6. Cacho-DíazB CuapaténcatlLD RodríguezJA Garcilazo-ReyesYJ Reynoso-NoverónN ArrietaO Identification of a high-risk group for brain metastases in non-small cell lung cancer patients J Neurooncol 2021 Oct 155 1 101 6 Search in Google Scholar

[18] Iuchi T, Shingyoji M, Itakura M, Yokoi S, Moriya Y, Tamura H, et al. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol. 2015 Aug;20(4):674–9. IuchiT ShingyojiM ItakuraM YokoiS MoriyaY TamuraH Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations Int J Clin Oncol 2015 Aug 20 4 674 9 Search in Google Scholar

[19] Remon J, Besse B. Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment. Front Oncol. 2018 Apr 11;8:88. RemonJ BesseB Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment Front Oncol 2018 Apr 11 8 88 Search in Google Scholar

[20] Berger A, Mullen R, Bernstein K, Alzate JD, Silverman JS, Sulman EP, et al. Extended Survival in Patients With Non-Small-Cell Lung Cancer-Associated Brain Metastases in the Modern Era. Neurosurgery. 2023 Jul 1;93(1):50–9. BergerA MullenR BernsteinK AlzateJD SilvermanJS SulmanEP Extended Survival in Patients With Non-Small-Cell Lung Cancer-Associated Brain Metastases in the Modern Era Neurosurgery 2023 Jul 1 93 1 50 9 Search in Google Scholar

[21] Singh R, Lehrer EJ, Ko S, Peterson J, Lou Y, Porter AB, et al. Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020 Mar;144:165–79. SinghR LehrerEJ KoS PetersonJ LouY PorterAB Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches Radiother Oncol J Eur Soc Ther Radiol Oncol 2020 Mar 144 165 79 Search in Google Scholar

[22] Balasubramanian SK, Sharma M, Venur VA, Schmitt P, Kotecha R, Chao ST, et al. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. Neuro-Oncol. 2020 Feb 20;22(2):267–77. BalasubramanianSK SharmaM VenurVA SchmittP KotechaR ChaoST Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis Neuro-Oncol 2020 Feb 20 22 2 267 77 Search in Google Scholar

[23] Sperduto PW, De B, Li J, Carpenter D, Kirkpatrick J, Milligan M, et al. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. Int J Radiat Oncol Biol Phys. 2022 Sep 1;114(1):60–74. SperdutoPW DeB LiJ CarpenterD KirkpatrickJ MilliganM Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors Int J Radiat Oncol Biol Phys 2022 Sep 1 114 1 60 74 Search in Google Scholar

[24] Churilla TM, Weiss SE. Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer. Curr Oncol Rep. 2018 May 7;20(7):54. ChurillaTM WeissSE Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer Curr Oncol Rep 2018 May 7 20 7 54 Search in Google Scholar

[25] Graber JJ, Cobbs CS, Olson JJ. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Use of Stereotactic Radiosurgery in the Treatment of Adults With Metastatic Brain Tumors. Neurosurgery. 2019 Mar 1;84(3):E168–70. GraberJJ CobbsCS OlsonJJ Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Use of Stereotactic Radiosurgery in the Treatment of Adults With Metastatic Brain Tumors Neurosurgery 2019 Mar 1 84 3 E168 70 Search in Google Scholar

[26] Gaspar LE, Prabhu RS, Hdeib A, McCracken DJ, Lasker GF, McDermott MW, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Whole Brain Radiation Therapy in Adults With Newly Diagnosed Metastatic Brain Tumors. Neurosurgery. 2019 Mar 1;84(3):E159–62. GasparLE PrabhuRS HdeibA McCrackenDJ LaskerGF McDermottMW Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Whole Brain Radiation Therapy in Adults With Newly Diagnosed Metastatic Brain Tumors Neurosurgery 2019 Mar 1 84 3 E159 62 Search in Google Scholar

[27] Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, et al. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2022 Jan;17(1):116–29. ThomasNJ MyallNJ SunF PatilT MushtaqR YuC Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2022 Jan 17 1 116 29 Search in Google Scholar

[28] Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet Lond Engl. 2016 Oct 22;388(10055):2004–14. MulvennaP NankivellM BartonR Faivre-FinnC WilsonP McCollE Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial Lancet Lond Engl 2016 Oct 22 388 10055 2004 14 Search in Google Scholar